Oxford Nanopore CEO’s $1 Billion Sales Goal Sends Stock Soaring

bloomberg

·

Original Report

↗ bloomberg

Oxford Nanopore Technologies Plc plans to focus on the most lucrative opportunities in gene sequencing, including quality control for mRNA vaccines, as it moves closer to break even in an increasingly competitive market.